Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/148044
Title: | Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. |
Author: | Baliakas, Panagiotis Moysiadis, Theodoros Hadzidimitriou, Anastasia Xochelli, Aliki Jeromin, Sabine Agathangelidis, Andreas Mattsson, Mattias Sutton, Lesley-Ann Minga, Eva Scarfò, Lydia Rossi, Davide Davis, Zadie Villamor i Casas, Neus Parker, Helen Kotaskova, Jana Stalika, Evangelia Plevova, Karla Mansouri, Larry Cortese, Diego Navarro López, Alba Delgado, Julio (Delgado González) Larrayoz, Marta Young, Emma Anagnostopoulos, Achilles Smedby, Karin E. Juliusson, Gunnar Sheehy, Oonagh Catherwood, Mark Strefford, Jonathan C. Stavroyianni, Niki Belessi, Chrysoula Pospisilova, Sarka Oscier, David Gaidano, Gianluca Campo Güerri, Elias Haferlach, Claudia Ghia, Paolo Rosenquist, Richard Stamatopoulos, Kostas |
Keywords: | Leucèmia limfocítica crònica Pronòstic mèdic Chronic lymphocytic leukemia Prognosis |
Issue Date: | Feb-2019 |
Publisher: | Ferrata Storti Foundation |
Abstract: | Chronic lymphocytic leukemia (CLL) patients with differentialsomatic hypermutation status of the immunoglobulin heavy vari-able genes, namely mutated or unmutated, display fundamentalclinico-biological differences. Considering this, we assessed prognosisseparately within mutated (M-CLL) and unmutated (U-CLL) CLL in 3015patients, hypothesizing that the relative significance of relevant indica-tors may differ between these two categories. Within Binet A M-CLLpatients, besides TP53abnormalities, trisomy 12 and stereotyped subset#2 membership were equivalently associated with the shortest time-to-first-treatment and a treatment probability at five and ten years afterdiagnosis of 40% and 55%, respectively; the remaining cases exhibited5-year and 10-year treatment probability of 12% and 25%, respectively.Within Binet A U-CLL patients, besides TP53abnormalities, del(11q)and/or SF3B1mutations were associated with the shortest time-to-first-treatment (5- and 10-year treatment probability: 78% and 98%, respec-tively); in the remaining cases, males had a significantly worse prognosisthan females. In conclusion, the relative weight of indicators that canaccurately risk stratify early-stage CLL patients differs depending on thesomatic hypermutation status of the immunoglobulin heavy variablegenes of each patient. This finding highlights the fact that compartmen-talized approaches based on immunogenetic features are necessary torefine and tailor prognostication in CLL. |
Note: | Reproducció del document publicat a: https://doi.org/10.3324/haematol.2018.195032 |
It is part of: | Haematologica, 2019, vol. 104, num. 2, p. 360-369 |
URI: | http://hdl.handle.net/2445/148044 |
Related resource: | https://doi.org/10.3324/haematol.2018.195032 |
ISSN: | 0390-6078 |
Appears in Collections: | Articles publicats en revistes (Fonaments Clínics) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
682535.pdf | 1.32 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.